- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different": HealthyWomen Wants to Educate US Women About Biosimilars
In October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. The daylong forum offered expert perspectives on the state of biosimilars in the United States, legislative and regulatory updates, and a look at challenges and opportunities for biosimilars to improve women’s access to treatment. This week on the podcast, we’re speaking with one of the presenters from that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.
In October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. The daylong forum offered expert perspectives on the state of biosimilars in the United States, legislative and regulatory updates, and a look at challenges and opportunities for biosimilars to improve women’s access to treatment. This week on the podcast, we’re speaking with one of the presenters of that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.
Sheldon is the chief clinical officer of the Oncology Nursing Society, where she oversees clinical strategy to support oncology nurses, advanced practice nurses, and researchers. She also practices as an oncology nurse practitioner at St Joseph Hospital in Nashua, New Hampshire.
Learn more about HealthyWomen at their website.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
